InMed (INM) - Amount of Cash per Share

InMed - graphic logo of issuer INM

Developing synthetic cannabinoids via the Integram platform to combat skin and eye pathologies requires colossal investment. An analysis of cash per share demonstrates a steady decline in liquidity due to high R&D expenses, while the metric remains around 2.05. However, the unique biosynthesis of pure substances provides InMed Pharmaceuticals (INM) with significant pricing power due to inelastic patient demand.

InMed Pharmaceuticals Inc (INM): Cash Funds per Share from 07/04/2022 to 11/09/2026

Comprehensive metric breakdowns and analytics for inmedpharma.com (INM)

- stock price and consensus target price:
- cash availability and cash flow indicators:
Summary company analysis:INM InMed Pharma
Signature product of InMed Pharmaceuticals

This metric assesses the level of net liquidity available per common share to determine the real value of assets. Analyzing current cash per share helps identify the risk of underinvesting in business development. The metric is calculated by dividing total cash holdings by the number of issued securities. For InMed Pharmaceuticals (INM), this reserve is critical during the pre-commercial sales period, as these funds provide financing for clinical trials of biosynthetic dermatology drugs.